Comments on the re-assessment study by Sharp et al. of Erschbamer et al.
Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden.
Matthias
M
Erschbamer
Karin
K
Pernold
Lars
L
Olson
D000818:Animals; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D005260:Female; D009043:Motor Activity / Q000502:physiology*; D011799:Quinazolines / Q000008:administration & dosage*; D020127:Recovery of Function / Q000502:physiology*; D013119:Spinal Cord Injuries / Q000188:drug therapy*; D001743:Urinary Bladder / Q000502:physiology*
C509204:PD168393; D011799:Quinazolines; C483803:Egfr protein, rat; D066246:ErbB Receptors